A randomised double blind, Placebo controlled Phase 3 study of the Bruton's Tyrosine Kinase (BTK) inhibitor, PCI-32765 (ibrutinib), in Combination with Bendamustine and Rituximab (BR) in subjects with

Project: Research

StatusFinished
Effective start/end date1/07/1330/09/14